These findings collectively confirm that SGLT2 inhibitors significantly reduce the risk of HHF in patients with type 2 diabetes, with relatively consistent benefits across agents, except for ertugliflozin, where evidence remains less conclusive. Here, SLC5A2 is linked to type 2 diabetes mellitus.